




UTILITY PATENT APPLICATION TRANSMITTAL		CERTIFICATE UNDER 37 C.F.R. 1.10	Docket No. IVD 1118-2
(Only for new nonprovisional application under 37 CFR 1.53(b))		Express Mail Label No.: EL676469444US Date of Deposit: September 16, 2003 I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to: Commissioner for Patents, Box Patent Application, Washington, DC 20231  Signature	
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO: Commissioner for Patents Box Patent Application Washington, DC 20231	
<div><div><div>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</div><div>2. <input checked="" type="checkbox"/> Specification Total Pages <input type="text" value="112"/> (preferred arrangement set forth below)<ul style="list-style-type: none">- Descriptive Title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R & D- Reference to Sequence Listing or a Table Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claim(s)- Abstract of the Disclosure</div><div>3. <input type="checkbox"/> Drawing(s) (35 USC 113) Total Sheets <input type="text" value="112"/></div><div>4. <input checked="" type="checkbox"/> Oath or Declaration/ Power of Attorney Total Sheets <input type="text" value="3"/><ul style="list-style-type: none">a. <input type="checkbox"/> Newly executed (original or copy)b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 16 completed)i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</div><div>5. <input type="checkbox"/> Application Data Sheet (See 37 CFR 1.76)</div></div><div><div>6. <input type="checkbox"/> CD-Rom or CD-R, Large Table or Computer Program (Appendix)</div><div>7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)<ul style="list-style-type: none">a. <input type="checkbox"/> Computer Readable Form (CFR)b. <input type="checkbox"/> Paper copy (identical to computer copy)c. <input type="checkbox"/> Statement verifying identity of above copies</div></div></div>			
ACCOMPANYING APPLICATION PARTS			
<div><div>8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</div><div>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney</div><div>10. <input type="checkbox"/> English Translation Document (if applicable)</div><div>11. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</div><div>12. <input checked="" type="checkbox"/> Preliminary Amendment</div><div>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</div><div>14. <input type="checkbox"/> Request and Certification under 35 U.S.C. 122(b)(2)(B)(i)</div><div>15. <input checked="" type="checkbox"/> Other: <u>Citation of References</u></div></div>			
16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76: <input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application no: <u>09/913,106</u> Prior Application Information: Examiner: <u>Rita J. Desai</u> Group Art Unit: <u>1625</u> For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.			
17. CORRESPONDENCE ADDRESS			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label or <input checked="" type="checkbox"/> Correspondence address below  27546			
Paul E. Dupont Sanofi-Synthelabo Inc. 9 Great Valley Parkway Malvern, PA 19355 Telephone No.: (610) 889-6338 Facsimile No.: (610) 889-8799		Respectfully submitted,  Paul E. Dupont Reg. No. 27,438	

22386 U.S. PTO
10/663124
09/16/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Divisional Under 37 C.F.R. 1.53(b)
 Application of: Jean-Philippe DUCOUX, Xavier
 EMONDS-ALT; Patrick GUEULE; and Vincenzo
 PROIETTO

Prior Application Serial No.: 09/913,106

Prior Filing Date: August 9, 2001

Prior Group Art Unit: 1625

Examiner: Desai, Rita J.

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label Number: EL676469444US

Date of Deposit: September 16, 2003

I hereby certify that this paper is being deposited with
 the United States Postal Service "Express Mail Post
 Office to Addressee" Service on the date indicated
 above and is addressed to:

Mail Stop Patent Application
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Signature

FOR: NOVEL PIPERIDINE DERIVATIVES, PROCESS FOR OBTAINING THEM AND
 PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Mail Stop Patent Application
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

FEE TRANSMITTAL FORM

The filing fee for the above-identified has been calculated as shown below:

<u>Claims as Filed</u>				Rate	Basic Fee \$750.00
Number Filed	Number Extra				
Total Claims	22	-20 =	2 X	\$ 18.00 =	36.00
Independent Claims	7	- 3 =	4 X	\$ 84.00 =	336.00
Multiple dependent claims(s), if any				\$280.00 =	
Total Filing Fee:					\$1,122.00

Please charge the filing fee of \$ 1,122.00 to Deposit Account No. 19-0091 and charge any additional fees under 37 CFR 1.16 which may be required, or credit any overpayment, to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.

☒ This application is being filed by "Express Mail" as of the date of this letter pursuant to
 37 CFR 1.10

Date:

9/16/03

Paul E. Dupont
 Reg. No. 27,438

Address:
 Patent Department
 Sanofi-Synthelabo Inc.
 9 Great Valley Parkway
 Malvern, PA 19355
 Telephone: (610) 889-6338
 Facsimile: (610) 889-8799

Application of: DUCOUX et al.

Docket No.: IVD 1118-2

Divisional of U.S. Application Serial No. 09/913,106

FOR: NOVEL PIPERIDINE DERIVATIVES, PROCESS FOR OBTAINING
THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING
THEM


CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EL676469444US

Date of Deposit: September 16, 2003

I hereby certify that this paper is being deposited with the United States
Postal Service "Express Mail Post Office to Addressee" Service on the
date indicated above, and is addressed to:

Commissioner for Patents, Box Patent Application, Washington, DC
20231


Signature